Substance
INSULIN LISPRO
Global reference: every product and company linked to this substance.
- cas: 133107-64-9
- ncit: C29123
- pubchem_cid: 118984450
- rxnorm: 86009
- unii: GFX7QIS1II
ADMELOG · ADMELOG SOLOSTAR · HUMALOG · insulin lispro [INN] · INSULIN LISPRO [JAN] · INSULIN LISPRO [USAN] · Insulin lispro [WHO-DD] · Insulin lispro protamine [WHO-DD] · LY-275585 · LY-900014 · LY275585 · LY900014
Revenue by product (3)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| ELI LILLY AND COMPANY COMMON STOCK | HUMALOG | Q4 2024 | $619.9M |
| ELI LILLY AND COMPANY COMMON STOCK | HUMALOG PEN | Q4 2024 | $619.9M |
| ELI LILLY AND COMPANY COMMON STOCK | HUMALOG | Q4 2024 | $619.9M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (7)
- ADMELOG · SANOFI ADS
- ADMELOG SOLOSTAR · SANOFI ADS
- HUMALOG · ELI LILLY AND COMPANY COMMON STOCK
- HUMALOG KWIKPEN · ELI LILLY AND COMPANY COMMON STOCK
- HUMALOG PEN · ELI LILLY AND COMPANY COMMON STOCK
- HUMALOG TEMPO PEN · ELI LILLY AND COMPANY COMMON STOCK
- HUMALOG · ELI LILLY AND COMPANY COMMON STOCK